Carve-out: omission of patented indications from a generic's product information

A carve-out removes indications or dosage forms still under patent from a generic's SmPC and leaflet, so it can launch for the unprotected uses.

Also known as: skinny label, skinny labelling, usage patent carve-out, indication carve-out

3 min readUpdated

Reviewed by Gosia Luksza, CEO at Regunaut

At a glance

Legal basis
Article 11 of Directive 2001/83/EC; Article 3(3)(b) of Regulation (EC) No 726/2004
What can be left out
Indications or dosage forms still covered by patent law when the generic is marketed
Where it is made
National phase for DCP and MRP products; one EU text for centralised generics
Sections affected
Typically SmPC 4.1, 4.2 and 5.1 and the matching leaflet text

How it works

A generic's product information must be consistent with that of its reference product. The last subparagraph of Article 11 of Directive 2001/83/EC makes one exception: for authorisations under Article 10, those parts of the reference product's summary of product characteristics that refer to indications or dosage forms still covered by patent law when the generic is marketed need not be included. Article 3(3)(b) of Regulation (EC) No 726/2004 contains the same exception for generics of centrally authorised products. The result is known as a carve-out or skinny label: the generic is authorised and sold for the off-patent uses only.

The carve-out exists because the substance patent usually expires before later second medical use patents, which protect a particular indication, dose regimen or patient group. Without it, a generic could not launch until the last such patent had gone. Regulators do not check patents; the applicant decides what to remove, country by country, since patents are national rights. In decentralised and mutual recognition procedures the full text is normally agreed in the European phase and the patented wording is removed in the national phase, typically from SmPC sections 4.1, 4.2 and 5.1 and the corresponding parts of the package leaflet. Safety information that is relevant to all patients stays in. For centrally authorised generics there is one product information for the whole EU, so a carve-out applies everywhere. When the patent expires, the holder adds the indication back by variation.

The Court of Justice addressed the mechanism in Warner-Lambert (C-423/17) in 2019. It held that when a generic applicant or holder tells the authority that it is leaving a patented indication out of the product information, that communication is a request to limit the marketing authorisation to the remaining indications. A carve-out does not settle the patent question, though. The originator can still argue that the generic is being prescribed, dispensed or reimbursed for the patented use, and courts in several countries have had to decide when a generic company is liable for such use.

A similar omission applies outside patent law. An indication protected by orphan market exclusivity, or by the one year of data exclusivity under Article 10(5), cannot be included in a generic's product information until that protection ends.

What goes wrong

Carving out the indication but leaving posology, pharmacodynamic text or leaflet wording that still describes the protected use; removing safety information along with the indication; applying one carve-out to all countries when the patent situation differs between them; forgetting to reinstate the indication after expiry, which leaves the generic with a narrower label than its competitors; and tenders or pharmacy substitution rules that treat the skinny-label product as interchangeable for every use, which is where most infringement disputes start.

Timing

The carve-out must be in place when the generic is placed on the market in the Member State concerned. In decentralised and mutual recognition procedures it is made in the national phase, in the 30 days after the procedure closes, and it can also be introduced or removed later by variation. Reinstating the indication should be timed for the day the patent or certificate expires in each country.

Carve-out: common questions

What is a skinny label?

It is the product information of a generic from which indications or dosage forms still protected by patent have been removed, so that the generic can be marketed for the unprotected uses. In the EU the legal basis is the last subparagraph of Article 11 of Directive 2001/83/EC, and the practice is usually called a carve-out.

Does a carve-out protect a generic company from patent infringement?

Not by itself. It shows that the company is not offering the product for the patented use, but the regulator does not assess patents, and the patent holder can still bring an action if the generic is in practice supplied for the protected indication. Liability depends on national patent law and on the steps the generic company took to prevent such use.

How is a carved-out indication added back?

By a variation to the marketing authorisation once the patent or supplementary protection certificate has expired in the Member State concerned. The wording was already assessed for the reference product, so the change is mainly administrative, but the SmPC, package leaflet and printed packaging materials all need updating, and the timing differs by country.

Sources

  1. EUR-Lex: Directive 2001/83/EC on the Community code relating to medicinal products for human use
  2. Court of Justice of the EU: Case C-423/17, Staat der Nederlanden v Warner-Lambert Company LLC, judgment of 14 February 2019
  3. CMDh: Questions and answers, including the Q&A on usage patents

Put your Carve-out question to Workbench

Workbench answers regulatory questions from EUR-Lex, EMA, national agencies and your own documents, with every claim linked to its source. Start free with welcome credits.